Numerous in vitro and in vivo studies(Powell et al, 2010) using differentclasses of PARP inhibitors have reported enhancement of the cytotoxicity ofradiation in a number of tumour types, including colorectal cancers (Calabrese et al, 2004) and gliomas (Dungey et al, 2009; Russo et al, 2009). Here, PARP1 is linked to central nervous system cancer.